Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT01203787 Completed - Clinical trials for Hepatocellular Carcinoma

Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)

Start date: December 2010
Phase: Phase 4
Study type: Interventional

Open-label study to evaluate the safety and tolerability of Sorafenib dose ramp-up (starting at a lower dose and then gradually increasing the dose) versus standard Sorafenib dosing in subjects with unresectable and/or metastatic hepatocellular carcinoma.

NCT ID: NCT01198704 Completed - Clinical trials for Hepatocellular Carcinoma

Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC)

EFAPRE
Start date: January 2009
Phase:
Study type: Observational

Results of liver transplantation, the best theoretical treatment for HCC, are limited by tumor recurrence. In order to limit this risk Milan criteria was proposed in 1996. However, these criteria are to restrictive and approximately 40% of patients denied by Milan criteria may be cured by liver transplantation. The purpose of this study was thus to prospectively evaluate factors predicting tumor recurrence after liver transplantation for HCC and then to reassess criteria for liver transplantation.

NCT ID: NCT01192971 Completed - Clinical trials for Advanced Hepatocellular Carcinoma

A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma

HCC
Start date: June 2010
Phase: Phase 2
Study type: Interventional

This phase II trial will be studying how well Apatinib working in patients with Hepatocellular carcinoma.

NCT ID: NCT01180959 Completed - Liver Cancer Clinical Trials

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Start date: April 14, 2011
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if the combination of AvastinTM (bevacizumab) and Tarceva (erlotinib hydrochloride) can help to control advanced liver cancer. The safety of this drug combination will also be studied.

NCT ID: NCT01177631 Completed - Clinical trials for Carcinoma, Hepatocellular

Proteomic Analysis of Human Hepatocellular Carcinoma

Start date: February 2009
Phase: N/A
Study type: Interventional

This is a pilot study to evaluate the difference between the protein expression between hepatocellular carcinoma and tumor with vessel invasion in Asian patients with hepatocellular carcinoma.

NCT ID: NCT01176604 Completed - Clinical trials for Unresectable Hepatocellular Carcinoma

Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma

Start date: August 4, 2010
Phase: N/A
Study type: Interventional

This trial studies how well yttrium Y 90 glass microspheres work in treating patients with hepatocellular carcinoma that cannot be removed by surgery. Radioactive drugs, such as yttrium Y 90 glass microspheres, may carry radiation directly to cancer cells and not harm normal cells.

NCT ID: NCT01171651 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma

Start date: August 2009
Phase: Phase 2
Study type: Interventional

The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously and intratumorally prior to standard sorafenib therapy.

NCT ID: NCT01165346 Completed - Clinical trials for Hepatocellular Carcinoma

Stereotaxic Irradiation of Hepatocellular Carcinoma

CKNO-HEP
Start date: August 31, 2009
Phase: Phase 2
Study type: Interventional

Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days for a total of 45 Gy.

NCT ID: NCT01157013 Completed - Clinical trials for Hepatocellular Carcinoma

Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular Carcinoma

Start date: January 2009
Phase: N/A
Study type: Interventional

Positron emission tomography (PET) with [18F]fluorodeoxyglucose (FDG-PET) evaluates cancer cell glycolysis(Warburg effect) as a surrogate for tumor response.The hypothesis of this study is that early changes in FDG-PET signal can predict sorafenib response in hepatocellular carcinoma (HCC).

NCT ID: NCT01147380 Completed - Clinical trials for Hepatocellular Carcinoma

Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation

MIAMINK
Start date: June 2010
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate feasibility and safety of the adoptive transfer of activated natural killer (NK) cells extracted from cadaveric donor liver graft perfusate for liver transplant recipients with hepatocellular carcinoma (HCC)